CSTL icon

Castle Biosciences

33.04 USD
--0.51
1.52%
At close Updated Nov 7, 4:00 PM EST
1 day
-1.52%
5 days
29.57%
1 month
44.15%
3 months
68.14%
6 months
93.78%
Year to date
17.83%
1 year
-0.81%
5 years
-30.85%
10 years
54.39%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823

0
Funds holding %
of 7,511 funds
0
Analysts bullish %
of 3 analysts
0
Positive news %
of 14 articles
Price charts implemented using Lightweight Charts™